- Home
- CCG vs SAVA Comparison
CCG vs SAVA Comparison
Compare CCG & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCG
- SAVA
- Stock Information
- Founded
- CCG 2014
- SAVA 1998
- Country
- CCG China
- SAVA United States
- Employees
- CCG N/A
- SAVA N/A
- Industry
- CCG
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- CCG
- SAVA Health Care
- Exchange
- CCG Nasdaq
- SAVA Nasdaq
- Market Cap
- CCG 75.1M
- SAVA 70.5M
- IPO Year
- CCG N/A
- SAVA N/A
- Fundamental
- Price
- CCG $0.85
- SAVA $1.77
- Analyst Decision
- CCG
- SAVA Buy
- Analyst Count
- CCG 0
- SAVA 3
- Target Price
- CCG N/A
- SAVA $54.50
- AVG Volume (30 Days)
- CCG 260.6K
- SAVA 822.2K
- Earning Date
- CCG 05-29-2025
- SAVA 05-08-2025
- Dividend Yield
- CCG N/A
- SAVA N/A
- EPS Growth
- CCG N/A
- SAVA N/A
- EPS
- CCG N/A
- SAVA N/A
- Revenue
- CCG $475,831,129.00
- SAVA N/A
- Revenue This Year
- CCG N/A
- SAVA N/A
- Revenue Next Year
- CCG $7.06
- SAVA N/A
- P/E Ratio
- CCG N/A
- SAVA N/A
- Revenue Growth
- CCG 5.20
- SAVA N/A
- 52 Week Low
- CCG $0.56
- SAVA $1.15
- 52 Week High
- CCG $2.39
- SAVA $42.20
- Technical
- Relative Strength Index (RSI)
- CCG 47.10
- SAVA 56.59
- Support Level
- CCG $0.83
- SAVA $1.45
- Resistance Level
- CCG $0.88
- SAVA $1.67
- Average True Range (ATR)
- CCG 0.06
- SAVA 0.11
- MACD
- CCG 0.00
- SAVA 0.05
- Stochastic Oscillator
- CCG 21.58
- SAVA 81.40
About CCG Cheche Group Inc.
Cheche Group Inc is engaged in the operation of providing insurance transaction services, Software-as-a-Service (SaaS) services and other services in China.. It is China's independent technology-empowered platform for auto insurance transaction services by digital auto insurance transaction premiums and insurance technology companies. The company has reshaped the traditional auto insurance distribution and services value chain to create a digital platform by improving operational efficiencies, reducing transaction costs, and expanding distribution channels. Its business scope ranges from digital insurance transactions, SaaS platforms for insurance intermediaries, AI-driven insurance pricing and underwriting services, auto insurance services for new energy vehicle (NEV) manufacturers, etc.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.